The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review.
about
Progress in treatment of ANCA-associated vasculitisInterventions for renal vasculitis in adultsIntravenous immunoglobulin as adjuvant therapy for Wegener's granulomatosisIntravenous immunoglobulin as adjuvant therapy for Wegener's granulomatosisInterventions for renal vasculitis in adultsWegener's granulomatosis: current and upcoming therapiesClinical review: Vasculitis on the intensive care unit -- part 2: treatment and prognosisRecent advances in anti-neutrophil cytoplasmic antibody-associated vasculitisClassification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosisTherapeutic plasma exchange and renal related vasculitis: therapeutic apheresis academy 2010.Cerebral vasculitis in adults: what are the steps in order to establish the diagnosis? Red flags and pitfalls.Interventions for renal vasculitis in adults. A systematic review.Small vessel vasculitis.Randomized trial of enteric-coated mycophenolate sodium versus mycophenolate mofetil in multi-system autoimmune disease.Glomerulonephritis due to antineutrophil cytoplasm antibody-associated vasculitis: an update on approaches to management.Pulmonary manifestations of anti-neutrophil cytoplasmic antibody (ANCA)-positive vasculitis.Primary systemic vasculitis: treatment of difficult cases.Intravenous cyclophosphamide and plasmapheresis in dialysis-dependent ANCA-associated vasculitisCurrent pharmacotherapy for the treatment of crescentic glomerulonephritis.EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis.ANCA-associated vasculitis: new options beyond steroids and cytotoxic drugs.Oral versus intravenous administration of cyclophosphamide: a case report.Improved survival in granulomatosis with polyangiitis: A general population-based study.Urological implications of cyclophosphamide and ifosfamide.Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts.The clinical course of ANCA small-vessel vasculitis on chronic dialysis.Update on the use of biologics in primary systemic vasculitides.Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials.Diagnosis and management of pulmonary vasculitis.Advances in therapy for ANCA-associated vasculitis.Long-term outcome of antineutrophil cytoplasmic antibody-associated small vessel vasculitis after renal transplantation.Cyclophosphamide treatment for idiopathic inflammatory myopathies and related interstitial lung disease: a systematic review.Twenty-five years of European Union collaboration in ANCA-associated vasculitis research.Cyclophosphamide in dermatology.Methylprednisolone pulse therapy and intravenous cyclophosphamide therapy combined with cocktail therapy in severe pediatric Henoch-Schönlein purpura nephritis patient.Paediatric anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis: an update on renal management.Hypersensitivity pneumonitis associated with azathioprine therapy in a patient with granulomatosis with polyangiitis.Long-term outcome of mycophenolate mofetil treatment for patients with microscopic polyangiitis: an observational study in Chinese patients.EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis.Effects of cyclophosphamide on the prognosis of Japanese patients with renal vasculitis associated with anti-neutrophil cytoplasmic antibody-positive microscopic polyangiitis.
P2860
Q21195258-1A7374CF-5FFD-4249-A149-0015E751E0F7Q24187038-013CF7BF-8ABD-42CB-9002-46B536F1077AQ24201647-9675BAF0-624E-478E-8CCA-6D1E90B74240Q24240077-4B008420-6DDA-4479-AC41-E51A53C7F709Q24242768-F8A2FB86-74DE-471F-8D7F-7940061A4732Q24804964-A7E5276D-ABD1-4B55-89F5-76BDF7D61860Q24811911-F6F208A0-72E2-4ABF-AB26-5F5060E3F594Q26751357-830068C1-2891-4D28-9FDD-CC81779B172FQ28389271-C2669408-3842-4188-9B2A-845A379F5E49Q30454083-5113AD60-64E1-45C4-BB20-FBEF724DEE42Q30676127-AA310983-9A5D-4AF6-B9E6-CC59AD573683Q33614376-CA96FEB3-DF70-4B84-BD09-20A8FC31DD40Q35011056-3DF9079B-ABCF-454B-AAE2-9826BF103C6FQ35310520-F0969591-99EB-4102-8B89-FD264DF414F5Q36234282-2325C761-485A-43A2-8FDA-4B00C0F3BAC0Q36370934-2A131D36-5F96-452A-98D6-47BA85FE42F3Q36458145-EA6375B5-ED9A-419D-BDBD-C4F3A8AE8425Q36583330-B8470AF7-F254-4F71-8FE3-1161B8B8B37AQ36623061-E7B561A4-12C4-447D-B919-B97DA6F27875Q36684589-4909BA4D-EE77-481A-8435-29AB5F9BB04DQ36802625-D7B412AE-E81C-4719-8D9E-9F3529997A86Q37041400-692A4708-3DFB-4C56-AD2C-A64F4E3D65C1Q37227906-C975E215-FA64-4620-9F2C-D4BBCD8BD83DQ37264407-EBD4E021-8089-4B39-832D-6284CEDCE2CCQ37369221-0122EFE2-9AE5-4FE7-90FD-8BE8ED39CA94Q37423440-932763DA-93EB-4802-9284-0753FBEF64B3Q37754811-8C5DC9C5-DBC7-407A-84E4-3761F514EDF1Q37926278-1EAFD681-E6CA-4F1F-BE7C-FF13D1E79AE0Q38033433-F5F42BB0-C738-45AA-BCA6-A09D59FEFE40Q38034940-989DB1C2-09F3-4B5D-A714-9146B2120E45Q38082794-6C209A9D-30F8-42CF-B299-0DD160E970D5Q38264788-8E8F9269-0DEB-4811-8D48-7C85409AB946Q38389839-EF0B8AC4-D479-42A3-A7A9-2D42423600D0Q38710150-8486CE86-4702-498A-959C-78346BA847B4Q38783714-4CB05FEA-26EE-4B4E-9AAD-934598ECA67CQ39072021-1409A627-9C52-41B5-9FEC-1F6FE9D58CB2Q40107035-696E0D93-C2E5-4434-AB92-9F5428A7D3D2Q40678626-30FB515C-A371-4E24-8C40-180097C55CB1Q40684657-A2118CDB-7349-4C97-849D-7749F620FF89Q41108889-43DF571A-131C-4D75-A4AD-217A9C1D926A
P2860
The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review.
description
2001 nî lūn-bûn
@nan
2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
The value of pulse cyclophosph ...... -analysis and critical review.
@ast
The value of pulse cyclophosph ...... -analysis and critical review.
@en
The value of pulse cyclophosph ...... -analysis and critical review.
@nl
type
label
The value of pulse cyclophosph ...... -analysis and critical review.
@ast
The value of pulse cyclophosph ...... -analysis and critical review.
@en
The value of pulse cyclophosph ...... -analysis and critical review.
@nl
prefLabel
The value of pulse cyclophosph ...... -analysis and critical review.
@ast
The value of pulse cyclophosph ...... -analysis and critical review.
@en
The value of pulse cyclophosph ...... -analysis and critical review.
@nl
P2093
P2860
P356
P1476
The value of pulse cyclophosph ...... -analysis and critical review.
@en
P2093
C O Savage
EUVAS (European vasculitis study group)
K de Groot
P2860
P304
P356
10.1093/NDT/16.10.2018
P407
P577
2001-10-01T00:00:00Z